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Introduction: Clinical practice guidelines are of increasing importance in the decision making for the
treatment of knee osteoarthritis. Inconsistent recommendations regarding the use of intra-articular
hyaluronic acid for the treatment of knee osteoarthritis have led to confusion among treating physicians.
Methods: Literature search to identify clinical practice guidelines that provide recommendations
regarding the use of intra-articular hyaluronic acid treatment for knee osteoarthritis was conducted.
Included guidelines were appraised using the AGREE II instrument. Guideline development method-
ologies, how the results were assessed, the recommendation formation, and work group composition
were summarized.
Results: Overall, 10 clinical practice guidelines were identiﬁed that met our inclusion criteria. AGREE II
domain scores were variable across the included guidelines. The methodology utilized across the
guidelines was heterogeneous regarding the evidence inclusion criteria, analysis of evidence results,
formulation of clinical practice recommendations, and work group composition. The recommendations
provided by the guidelines for intra-articular hyaluronic acid treatment for knee osteoarthritis are highly
inconsistent as a result of the variability in guideline methodology. Overall, 30% of the included
guidelines recommended against the use of intra-articular hyaluronic acid in the treatment of knee
osteoarthritis, while 30% deemed the treatment an appropriate intervention under certain scenarios.
The remaining 40% of the guidelines provided either an uncertain recommendation or no recommen-
dation at all, based on the high variability in reviewed evidence regarding efﬁcacy and trial quality.
Conclusion: There is a need for a standard “appropriate methodology” that is agreed upon for
osteoarthritis clinical practice guidelines in order to prevent the development of conﬂicting recom-
mendations for intra-articular hyaluronic acid treatment for knee osteoarthritis, and to assure that
treating physicians who are utilizing these guidelines are making their clinical decisions on the best
available evidence. At present, the inconsistent recommendations provided for intra-articular hyaluronic
acid treatment make it difﬁcult for clinical professionals to determine its appropriateness when treating
patients with knee osteoarthritis.
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Clinical practice guidelines (CPGs) have been developed as a
teaching tool to help direct the treating healthcare professional in
the care of their patients. They were initially developed heavily
based on expert opinion. Although CPGs still involve an expert
panel, they are increasingly evidence based. Hence, CPGs have a
growing inﬂuence on clinical practice due to a movement towardr HS Journals, Inc. This is an open
an@mednet.ucla.eduthe use of evidence-based medicine in clinical decision making [1].
Increasing healthcare costs are also a driving inﬂuence for the
development of CPGs for clinical decision making, as a tool for
limiting healthcare expenditure on treatments not proven to be
effective [2]. Every patient requires treatment decisions based on
their speciﬁc situation. CPGs are designed to provide information
from available evidence to be considered by the treating physician
and their patients when making a treatment decision, but they are
not intended to create uniformity and replace treatment decisions
of individual patients [3]. Hence, CPGs are intended to provide
clinical beneﬁt by educating physicians, other caregivers, and
patients on the most effective documented available treatment
methods. Unfortunately, there are limitations in the developmentaccess article under the CC BY-NC-ND license
Table 1
PubMed search strategy
PubMed Found articles
1. Osteoarthritis (title) 16,963
2. Treatment OR Recommendations (title) 8,371,303
3. Humans AND Osteoarthritis (MeSH terms) 38,960
4. Knee 117,257
5. 1 AND 2 AND 3 AND 4 4238
6. Guideline OR Recommendation 184,951
7. 5 AND 6 155
PubMed – 155 Arcles
Title Screen: 102 Arcles Excluded
Exclusion Criteria:
Not Guideline: 59 Arcles
Not Hyaluronic Acid: 39 Arcles
Not Knee: 3 Arcles
Duplicate: 1 Arcle
Abstract Screen: 33 Arcles Excluded
Exclusion Criteria:
Not Guideline: 22 Arcles
Not Hyaluronic Acid: 7 Arcles
Not Most Recent Version: 4 Arcles
Relevant for Full text screen: 
20 Arcles
Full Text Screen: 17 Arcles Excluded
Exclusion Criteria:
Not Guideline: 5 Arcles
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tions are accentuated when more than one set of CPGs are
developed on a condition.
Differences in the methods used in the development of the CPG
often lead to inclusion of different evidence and techniques used
in development of recommendations, creating inconsistent rec-
ommendations between guidelines for the same treatment [5].
In general, new CPGs are developed by a designed literature
review with guidelines developed by a working group. The work-
ing group provides expert opinion on the integration of standards
of clinical practice with a literature review. However, the expert
opinions from the CPG working group can interject bias in
recommendations based on anecdotal personal experience, or
misinterpretation of the available evidence [4]. The potential for
bias and misinterpretation from the CPG can be reduced but is not
eliminated by utilizing a robust, multidisciplinary working group
[6]. A potential area of bias is when patient preferences (an
important factor in clinical decision making [7]) are not considered
when guideline recommendations are formed. This could result in
treatment recommendations that are developed based on low-cost
implications or other societal impacts, not the sole demonstration
of efﬁcacy for the patient [4].
CPGs may vary in their quality, and the differentiation between
high- and low-quality CPGs is essential in the dissemination of
appropriate recommendations to clinical decision makers.
Unfortunately, a lack of deﬁned and generally accepted method-
ologies for CPG formation makes this differentiation difﬁcult [5].
There has been a surge of CPG development on osteoarthritis
(OA) treatment, perhaps reﬂecting the increasing prevalence of OA
as a cause of disability, particularly in developed countries [1].
Several organizations developed their own CPGs for knee OA, and
the quality of these guidelines is highly variable. Assessment tools
such as the AGREE II tool have been created to aid in the evaluation
of guideline quality [8], yet there is still no “standard” method-
ology for a group to utilize when formulating a CPG [5]. An
example of the variable methodology used in guideline develop-
ment with different conclusions and recommendations is evident
in the proposed guidelines for the treatment of knee OA with
intra-articular hyaluronic acid (IA-HA) [9–18].
The inconsistencies between CPG recommendations for the
IA-HA treatment have brought the variability of methodology
behind these guidelines into question [19]. In addition, the con-
ﬂicting recommendations have led to confusion among treating
physicians. This study aims to analyze the methodology used by
the current CPGs for knee OA treatment using IA-HA, and compare
the recommendation formulation process used by each of these
CPGs. The treating physician can be better informed and directed
by understanding the strengths and weaknesses of the present
IA-HA guidelines for OA. We will attempt to bring some clarity to
this issue.Not Hyaluronic Acid: 3 Arcles
Not English: 2 Arcles
Duplicate: 1 Arcle
Not Most Recent Version: 6 Arcles
Online Search Engines: 2 Arcles
Arcles to be Included: 10 Arcles
Naonal Guideline Clearing House: 1 Arcle
Reference Lists: 3 Arcles
Arcles Included from PubMed:
3 Arcles
Content Expert: 1 Arcle
Fig. 1. Screening Process.Methods
Selection of guidelines
We conducted a comprehensive search of PubMed (Table 1)
and multiple online sources to identify published guideline rec-
ommendations on the use of IA-HA treatment for the management
of knee OA (Fig. 1). Speciﬁcally, we conducted additional online
searches using Google, Yahoo, and National Guideline Clearing-
house. We used the following keywords in each of our searches:
hyaluronic acid/hylan/hyaluronate/viscosupplementation, guide-
line, recommendation, and knee osteoarthritis. We then searched
reference lists of the guidelines and articles identiﬁed andcontacted multiple experts in order to attempt to ensure that we
did not miss any relevant guidelines.
Guidelines were deﬁned as “a set of systematically developed
statements to assist practitioner and patient decisions about
appropriate healthcare for one speciﬁc clinical condition or disease
area” [20]. Publications that did not include recommendations for
clinical practice on the management of knee OA (e.g., systematic
reviews and service documents) were excluded. Since guidelines
could change based on current information, only the most recent
version of each guideline was included.Assessment of quality of reporting
The AGREE II instrument was used to assess the quality of each
guideline [8]. The AGREE II instrument was developed by the
Appraisal of Guidelines Research and Evolution (AGREE) Collabo-
ration. The AGREE instrument addresses 23 questions under six
domains: (1) scope and purpose, (2) stakeholder involvement,
(3) rigor of development, (4) clarity and presentation, (5) applic-
ability, and (6) editorial independence. The AGREE instrument uses
R.D. Altman et al. / Seminars in Arthritis and Rheumatism 45 (2015) 132–139134a 7-point Likert scale: ranging from “strongly agree” to “strongly
disagree” [8].
In addition to the AGREE II criteria, the following variables were
assessed with respect to recommendations for the use of IA-HA: (1)
the strength of the clinical evidence included in the guideline, (2)
model used for recommendation formation, (3) measurement tool of
clinical signiﬁcance, (4) consideration of patient opinion in formu-
lating the recommendation, and (5) professions represented in the
recommendation formulation group. The strength of the recom-
mendation for the use of IA-HA for the treatment of knee OA was
documented. Two reviewers (M.P. and E.N.) independently reviewed
each guideline, and any disagreements were resolved via consensus.
If consensus could not be reached, a third reviewer was consulted.
Analysis
For each guideline, mean scores for each of the six AGREE II
domains were calculated as per the recommendations by the
developers. The scores were standardized as a percentage of the
maximum possible score for each domain using the following
formula [20]:
score obtained –minimum possible scoreð Þ
maximum possible score –minimum possible scoreð Þ  100
As suggested by the instructions for the use of the AGREE II
instrument, a single quality score was not derived for each guide-
line from the individual domain scores. Each domain of the AGREE
II tool is reported independent from one another, as it is felt to beTable 2
Knee OA guideline details
Association Year Country Recommendation
Osteoarthritis Research
Society International
(OARSI)
2014 USA Uncertain—varying quality of evidence and
conﬂicting results
National Institute for
Health and Care
Excellence (NICE)
2014 UK Do not recommend—uncertainty and varyin
quality throughout evidence. Hyaluronic
is deemed to not be cost-effective
Veterans Affairs/
Department of
Defense (VA/DoD)
2014 USA Uncertain–insufﬁcient evidence available;
however, IA-HA may be considered if oth
treatment options are unsuccessful
American Academy of
Orthopaedic
Surgeons (AAOS)
2013 USA Do not recommend—based on a lack of IA-
efﬁcacy, not potential harm. High variabi
the quality of current evidence noted.
American College of
Rheumatology (ACR)
2012 USA No recommendation made regarding the u
IA-HA for initial knee OA management;
however, IA-HA is recommended for pati
Z75 that have not had satisfactory clinic
response to acetaminophen
American Academy of
Family Physicians
(AAFP)
2012 USA Recommended as a consideration for severe
OA cases when other treatment options h
been unsuccessful
Royal Australian College
of General
Practitioners (RACGP)
2009 Australia Grade C recommendation—there is some
evidence to suggest that IA-HA is of som
beneﬁt for OA of the knee
National Collaborating
Centre for Chronic
Conditions (NCC-CC)
2008 UK Do not recommend—Highly variable eviden
regarding IA-HA efﬁcacy, deemed not cos
effective
Agency for Healthcare
Research and Quality
(AHRQ)
2008 USA Uncertain—due to variability in trial quality
unclear signiﬁcance
European League
Against Rheumatism
(EULAR)
2003 France No recommendation made regarding the u
IA-HA for initial knee OA management;
however, acknowledgement of potential
efﬁcacy
USA—United States of America, UK—United Kingdom, N/A—not applicable, GP—generalinappropriate to merge the scores into a single quality score [8].
Additionally, the aforementioned variables were analyzed and
summarized for each guideline.Results
Guideline characteristics and results
Our search strategy identiﬁed 10 guidelines focusing on the use
of IA-HA for the management of knee osteoarthritis that met our
inclusion criteria [9–18]. The guidelines were published between
2003 and 2014, and they were published in the United States
(USA) (6 guidelines), United Kingdom (2 guidelines), Australia
(1 guideline), and France (1 guideline) (Table 2). The publishing
associations of the guidelines provide their services and guidelines
to a variety of different member demographics: Osteoarthritis
Research Society International (OARSI) has 1151 members distrib-
uted globally; American Academy of Orthopaedic Surgeons (AAOS)
has 38,000 orthopedic surgeon members (86.5% US and 13.5%
international); American College of Rheumatology (ACR) has 9317
members; American Academy of Family Physicians (AAFP) has
115,900 family physician members from the USA; Royal Australian
College of General Practitioners (RACGP) has 26,000 members
(over 22,000 of these members are general practitioners); National
Collaborating Centre for Chronic Conditions (NCC-CC) is a depart-
ment within the Royal College of Physicians, which has 29,472
members; and European League Against Rheumatism (EULAR) hasMembers Brief mission statement
1151 Members
distributed globally
Prevention and treatment of osteoarthritis
through the promotion and presentation of
research, education, and the worldwide
dissemination of new knowledge
g
acid
N/A, does not provide
membership
Improve outcomes for people using the NHS and
other public health and social care services
er
N/A, does not provide
membership
N/A, no applicable mission statement
HA
lity in
38,000 Orthopedic
surgeons
Serving (orthopedics) to provide the highest
quality musculoskeletal care
86.5% US and 13.5%
international
se of
ents
al
9317 Members Advancing rheumatology
knee
ave
115,900 Family
physicians from USA
To improve the health of patients, families,
and communities by serving the needs of
members with professionalism and creativity
e
26,000 Members 4
22,000 GPs
To improve the health and well-being of all
people in Australia by supporting GPs, general
practice registrars, and medical students
ce
t-
A department of
the Royal College of
Physicians, which has
29,472 members
A collaborative, multiprofessional center
undertaking commissions to develop clinical
guidance for the NHS in England and Wales
and N/A, does not provide
membership
To produce evidence to make healthcare safer,
higher quality, more accessible, equitable, and
affordable
se of 19 Healthcare
organizations from
various countries
within Europe
To stimulate, promote, and support the research,
prevention, treatment, and rehabilitation of
rheumatic diseases
practitioner, IA-HA—intra-articular hyaluronic acid, and OA—osteoarthritis.
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Europe. The Agency for Healthcare Research and Quality (AHRQ),
Veterans Affairs/Department of Defense (VA/DoD), and National
Institute for Health and Care Excellence (NICE) organizations do
not provide membership options (Table 2). These associations have
varying target audiences, with the primary focus including ortho-
pedic surgeons, rheumatologists, and general practitioners.
Recommendations regarding the use of IA-HA varied across the
guidelines (Table 2). Three of 10 (30.0%) guidelines recommend against
the use of IA-HA in the treatment of knee OA [9,11,12]. Two of the
guidelines that recommend against the use of IA-HA did so because
the treatment was deemed “not cost-effective,” as opposed to a lack of
efﬁcacy or potential harm [11,12]. The third guideline that strongly
recommended against the use of IA-HA based on their recommenda-
tion on a lack of efﬁcacy, not potential harm of the treatment [9].
Three of 10 (30.0%) guidelines recommended use of IA-HA in
the treatment of knee OA [13,14,16]. The recommendations were
based on speciﬁc scenarios in two of the guidelines: IA-HA is to be
considered for patients 475 years old who have not had satisfac-
tory clinical response to acetaminophen treatment [13], and IA-HA
is to be considered for moderate to severe cases of knee OA when
other treatment options have been unsuccessful [14]. The third
guideline states that IA-HA should be considered as a knee OA
treatment due to the representation of some clinical beneﬁt within
the reviewed evidence [16].
Three of 10 (30.0%) guidelines describe their recommendation
of IA-HA as “uncertain” [10,17,18]. These guidelines do not deﬁn-
itively recommend for or against IA-HA due to the high variability
in the available evidence regarding efﬁcacy and trial quality, as
well as the lack of available evidence. Additionally, one of the 10
(10.0%) guidelines did not provide any recommendation regarding
the use of IA-HA as a treatment for knee OA [15]. This guideline did
acknowledge the potential efﬁcacy of IA-HA within the evidence
but did not include an explicit recommendation for its use.
AGREE II guideline appraisal
Each guideline was independently appraised by two reviewers
(M.P. and E.N.), using the AGREE II appraisal tool [8]. The mean
scores and standard deviation for all 6 domains within the AGREE
II instrument were calculated as outlined in the methods (Table 3).
Most guidelines scored poorly in the “Applicability” domain, while
most guidelines scored well in the “Scope and Purpose” domain.
Scores were variable across the guidelines with respect to each
domain, suggesting a high variability in guideline quality. Typically
the OARSI, NICE, AAOS, and NCC-CC guidelines scored higher than
the other guidelines. The NICE and NCC-CC guidelines scored
highest in the “Applicability” domain mainly due to the inclusionTable 3
AGREE II checklist scores for knee OA guidelines
Guideline
Scope and purpose
(mean %, SD)
Stak
invo
(mea
Osteoarthritis Research Society International (OARSI) 86.11 7 19.64 80.5
National Institute for Health and Care Excellence (NICE) 100 7 0 10
Veterans Affairs/Department of Defense (VA/DoD) 80.55 7 11.78 75.0
American Academy of Orthopaedic Surgeons (AAOS) 94.44 7 7.86 86.1
American College of Rheumatology (ACR) 77.78 7 31.43 74.9
American Academy of Family Physicians (AAFP) 27.78 7 23.57 13.8
Royal Australian College of General Practitioners (RACGP) 88.89 7 15.72 88.8
National Collaborating Centre for Chronic Conditions
(NCC-CC)
83.33 7 23.57 94.4
Agency for Healthcare Research and Quality (AHRQ) 100 7 0 66.6
European League Against Rheumatism (EULAR) 91.67 7 11.79 66.6
SD—standard deviation.of resource implications within these two guidelines, while most
other guidelines did not provide this information. The generally
low scores in the “Applicability” domain also arose from a lack of
reporting of facilitators and barriers for guideline application.
Review of guideline development methodology
The developers of each of the guidelines utilized different
methodologies, which may account for the different recommen-
dations. The inclusion criteria for each guideline are variable,
resulting in inconsistent evidence pools used to determine rec-
ommendations. Fig. 2 provides a summary of the evidence used by
each guideline in comparison to the evidence found in the 2012
systematic review by Rutjes et al. [21], in the 2006 systematic
review by Bellamy et al. [22], and in a comprehensive search of
trial reference lists (considered to be “All Available Evidence” in
Figure 1). The “All Available Evidence” pool consists of 25 system-
atic reviews and 110 RCTs. The evidence used by each guideline to
form their recommendations was as follows: OARSI used three
systematic reviews as the basis for their recommendation, NICE
used one systematic review and 24 additional RCTs, VA/DoD used
one systematic review and four RCTs, AAOS used 20 RCT’s, ACR
used three systematic reviews, AAFP used two systematic reviews,
RACGP used one systematic review and three RCT’s, NCC-CC used
one systematic review and six RCT’s, AHRQ used seven systematic
reviews, and EULAR used eight RCTs (Fig. 2). The majority of the
guidelines [8 of 10 (80.0%)] included the results from systematic
reviews in their recommendation formulation [10–14,16–18],
while two of 10 (20.0%) did not consider results from systematic
reviews when determining their recommendation [9,15]. Figure 2
provides an overview of the evidence included in each of the
systematic reviews within “All available evidence” [21–45].
Included evidence was highly variable across all guidelines, dem-
onstrating that there are no standard inclusion criteria when
formulating a guideline regarding the use of IA-HA (Fig. 3).
The reported limitations of the evidence of IA-HA treat-
ment are presented in Table 4. Four of 10 guidelines (40.0%)
indicate that a lack of inconsistent trial results limit the
credibility of the body of evidence [10,14,17,18]. Six of 10
(60.0%) guidelines describe high variability in trial quality as a
limitation in the evidence [9–12,16,17]. Inadequate differentia-
tion between the results of speciﬁc IA-HA products was reported
to be a limitation of the evidence in three of 10 (30.0%) guide-
lines [15–17]. One of 10 (10.0%) guidelines presented variability
of safety data for IA-HA as a limitation in the body of evidence
[10].
The guideline developers also utilized a variety of methodo-
logical assessments to formulate their recommendationseholder
lvement
n %, SD)
Rigor and
development
(mean %, SD)
Clarity of
presentation
(mean %, SD)
Applicability
(mean %, SD)
Editorial
independence
(mean %, SD)
5 7 19.64 86.46 7 4.42 100 7 0 22.915 7 32.41 100 7 0
0 7 0 91.66 7 0 88.88 7 7.85 70.83 7 5.89 95.83 7 5.89
0 7 11.79 59.38 7 1.48 77.78 7 0 29.17 7 0 58.34 7 11.79
1 7 3.92 93.75 7 0 100 7 0 22.92 7 20.62 100 7 0
9 7 3.92 72.22 7 7.86 72.22 7 23.57 18.75 7 26.52 50 7 0
9 7 11.79 27.08 7 0 55.55 7 31.42 35.4 7 20.65 37.5 7 17.68
9 7 7.86 86.46 7 10.32 97.22 7 3.93 33.33 7 11.78 75 7 35.36
4 7 0 80.21 7 4.42 94.44 7 0 77.08 7 20.62 70.83 7 29.46
6 7 39.29 67.71 7 16.20 41.66 7 35.36 25 7 11.79 75 7 35.36
6 7 31.42 72.79 7 14.91 83.33 7 15.71 43.75 7 2.95 20.83 7 29.46
RCT – Randomized controlled trial, SR – Systemac review, MA – Meta-analysis, OARSI - Osteoarthris Research Society Internaonal, NICE -
Naonal Instute for Health and Care Excellence, VA/DoD - Veterans Aﬀairs/ Department of Defense, AAOS - American Academy of Orthopaedic
Surgeons, ACR - American College of Rheumatology, AAFP - American Academy of Family Physicians, RACGP - Royal Australian College of General
Praconers, NCC-CC - Naonal Collaborang Centre for Chronic Condions, AHRQ - Agency for Healthcare Research and Quality, EULAR -
European League Against Rheumasm
* All available evidence column derived from Rutjes, 2012[21] and Bellamy, 2006[22] , as well as hand-selected arcles. 
0
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Fig. 2. Evidence included in recommendation formation.
RCT—randomized controlled trial, SR—systematic review, MA—meta-analysis, OARSI—Osteoarthritis Research Society International, NICE—National Institute for Health and
Care Excellence, VA/DoD—Veterans Affairs/Department of Defense, AAOS—American Academy of Orthopaedic Surgeons, ACR—American College of Rheumatology, AAFP—
American Academy of Family Physicians, RACGP—Royal Australian College of General Practitioners, NCC-CC—National Collaborating Centre for Chronic Conditions, AHRQ—
Agency for Healthcare Research and Quality, EULAR—European League Against Rheumatism.
*All available evidence column derived from Rutjes et al. [21] and Bellamy et al. [22], as well as hand-selected articles.
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analysis perspective. Half [5 of 10 (50.0%)] of the guidelines used
a standardized mean difference as the measure of efﬁcacy when
forming recommendations [10,11,13,15,17]. Two of the 10 (20.0%)
guidelines used a minimum clinically important improvement
(MCII) to assess efﬁcacy results [9,17], 2 of the 10 (20.0%)
guidelines calculated a weighted mean difference [12,17], onelvl – level
0 20 40 60 80 100
Aggarwal, 2004
Arrich, 2005
Bannuru, 2009
Bannuru, 2011
Bannuru, 2014
Bellamy, 2006
Brander, 2009
Brzusek, 2008
Cheng, 2012
Colen, 2012
Divine, 2007
Health Quality Ontario, 2005
Lo, 2003
Migliore, 2010
Miller, 2013
Modawal, 2005
Pagnano, 2005
Pai, 2014
Reichenbach, 2007
Reid, 2013
Rodriguez, 2013
Rutjes, 2012
Strand, 2006
Trigkilidas, 2013
Wang, 2004
Evidence Included in Systemac 
Reviews
# of lvl 1 evidence arcles included
Fig. 3. Evidence included in IA-HA systematic reviews and meta-analyses.
lvl ¼ level.(10.0%) guideline considered Quality Adjusted Life-Years (QALY)
[12], one (10.0%) guideline used an expert review and opinion
process to deem signiﬁcance, and one (10.0%) guideline used the
National Health and Medical Research Council (NHMRC) body of
evidence assessment matrix to analyze the efﬁcacy results from
the evidence that met inclusion criteria [16]. One guideline
(10.0%) did not provide any speciﬁc methodological assessments
used when formulating their recommendations [14]. This varia-
bility in methodology suggests that there is not standard,
universally accepted procedure for the evidence assessment for
an association who is formulating guideline recommendations
for knee OA.
The guidelines also used multiple recommendation formulation
tools when transitioning from the available evidence to a clinical
recommendation (Table 5). The NICE and ACR guidelines used the
GRADE recommendation tool to derive clinical recommendations
[11,13], while the OARSI and EULAR guidelines used a Delphi
method [10,15] (The OARSI guideline used a combination of
RAND/UCLA Appropriateness method and Delphi methods). The
VA/DoD guideline utilized the US Preventive Services Task Force
(USPSTF) grading system. The AAOS guideline developed and
utilized a unique system of evidence quality assessment and
recommendation formation derived from their criteria and method-
ology [9]. The RACGP guideline used the NHMRC's “Additional levels
of evidence and grades for recommendations for developers of
guidelines” criteria. The NCC-CC guideline used recommendation
methods taken from the 2007 NICE guideline manual, the “creating
guideline recommendations” chapter. The AHRQ recommendations
were derived on expert opinion regarding the pooled trial results
from the included evidence, and the AAFP did not explicitly deﬁne
their methodology in formulating IA-HA recommendations.
The guidelines were also inconsistent in their representation of
all relevant clinical professionals within the recommendation
work group (Table 5). The guidelines utilized experts from ortho-
pedics [8/10 guidelines (80.0%)], rheumatology [9/10 guidelines
(90.0%)], general practice/family medicine [8/10 guidelines
(80.0%)], rehabilitation [6/10 guidelines (60.0%)], geriatrics [3/10
Table 4
Reported limitations within the IA-HA treatment body of evidence
Association
Inconsistent
trial results
Variable trial
quality
Inadequate differentiation
between product results
Inconsistent safety
proﬁles
Osteoarthritis Research Society International (OARSI) Yes Yes No Yes
National Institute for Health and Care Excellence (NICE) No Yes No No
Veterans Affairs/Department of Defense (VA/DoD) Yes No No No
American Academy of Orthopaedic Surgeons (AAOS) No Yes No No
American College of Rheumatology (ACR) No No No No
American Academy of Family Physicians (AAFP) Yes No No No
Royal Australian College of General Practitioners (RACGP) No Yes Yes No
National Collaborating Centre for Chronic Conditions (NCC-CC) No Yes Yes No
Agency for Healthcare Research and Quality (AHRQ) Yes Yes No No
European League Against Rheumatism (EULAR) No No Yes No
Yes—guideline has reported as a limitation, No—guideline did not report as a limitation.
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cology [2/10 guidelines (20.0%)]. The ACR CPG also included a pain
specialist [13]. In addition to the variability in work group
composition, the inclusion of patient advocates within the work
group was seen within four of 10 guidelines (40.0%).Discussion
We identiﬁed and appraised 10 published CPGs for IA-HA
treatment of knee OA, which provided inconsistent recommenda-
tions. The included guidelines varied greatly in terms of AGREE II
domain scores, displaying inconsistent quality of reporting
throughout the guidelines for this treatment. The primaryTable 5
Knee OA guideline methodology
Guideline
Measure of clinical
signiﬁcance Model for recommendation formulation
Osteoarthritis Research
Society International
(OARSI)
SMD RAND/UCLA Appropriateness method
and Delphi method
National Institute for
Health and Care
Excellence (NICE)
SMD GRADE-derived software “GRADEpro”
Veterans Affairs/
Department of
Defense (VA/DoD)
Expert Opinion USPSTF rating system
American Academy of
Orthopaedic
Surgeons(AAOS)
MCII AAOS system of evidence quality
assessment and recommendation
formulation
American College of
Rheumatology (ACR)
SMD GRADE approach
American Academy of
Family Physicians
(AAFP)
Not deﬁned within
guideline
Not deﬁned within guideline
Royal Australian
College of General
Practitioners (RACGP)
NHMRC body of
evidence
assessment
matrix
NHMRC additional levels of evidence
and grades for recommendations for
developers of guidelines
National Collaborating
Centre for Chronic
Conditions(NCC-CC)
WMD and QALY NICE guideline manual, 2007 “Creating
guideline recommendations”
methods
Agency for Healthcare
Research and Quality
(AHRQ)
SMD, WMD, and
MCII
Expert analysis of pooled trial results
European League
Against Rheumatism
(EULAR)
SMD Five-stage Delphi questionnaire
technique
SMD—standardized mean difference, MCII—minimum clinically important difference, WM
—National health and medical research council, QALY—quality adjusted life year, NICE
Orthopaedic Surgeons, RAND—Research And Development Company, UCLA—Universi
development, and evaluation.limitation of most guidelines was within the “Applicability”
domain of the AGREE II tool, as these guidelines generally lacked
information regarding barriers to the guidelines application,
potential resource implications of the recommendations provided,
tools for putting the guideline into practice, and monitoring/
auditing criteria. There was a large difference in scores between
guidelines within the “Editorial Independence” domain, mainly
due to the inconsistent reporting of competing interests of work
group members. The inconsistent AGREE II scores for the guide-
lines within all six domains recorded demonstrate the wide range
of quality within the available CPG literature regarding IA-HA
injection for knee OA.
As well as inconsistent AGREE II scores, the methodological
processes utilized in CPG development by each organization wasConsideration of patient
opinion Clinical members of work group
Patient advocate included
in work group
Rheumatologists, Orthopedic surgeons,
physiotherapists, primary care physician,
rehabilitation specialist, and patient advocate
Patient advocate included
in work group
Rheumatologists, Orthopedic surgeons, general
practitioners, geriatrician, pharmacist, registered
nurse, and patient advocates
No patients in work group Rheumatologists, orthopedic surgeon, registered
nurse, nurse practitioner, rehabilitation
specialist, chiropractor, and pharmacist
No patients in work group Orthopedic surgeons, rheumatologists,
physiotherapist, and family physician
No patients in work group Primary care physicians, rheumatologists,
orthopedic surgeon, physiatrists, geriatricians,
physical, and occupational therapists
No patients in work group Single author and family physician
Patient advocate included
in work group
Rheumatologists, general practitioner, registered
nurse, physiotherapist, and patient advocate
Patient advocate included
in work group
Rheumatologists, general practitioner,
physiotherapist, geriatrician, orthopedic
surgeons, and patient advocate
No patients in work group Orthopedic surgeons, rheumatologists, registered
nurse, and family physician
No patients in work group Rheumatologists and orthopedic surgeons
D—weighted mean difference, USPSTF—US Preventive Services Task Force, NHMRC
—National Institute for Health and Care Excellence, AAOS—American Academy of
ty of California Los Angeles, GRADE—grading of recommendations assessment,
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tions provided and methodology of guidelines convey uncertainty
as to the appropriateness of the methodology used. A highly
heterogeneous pool of relevant evidence was included by each
guideline, demonstrating a lack of universally accepted inclusion
criteria for evidence when formulating a CPG for IA-HA treatment
of knee OA. As a result of heterogeneous evidence inclusion
throughout the guidelines, inconsistent recommendations regarding
the efﬁcacy and safety of IA-HA were formulated by the guidelines.
The guidelines differ in their recommendations regarding safety,
efﬁcacy, evidence quality, and consistency of trial results. The AAOS,
NICE, and NCC-CC guidelines all provided recommendations against
the use of IA-HA; however, their reasoning for these recommenda-
tions is generally conﬂicting. The AAOS recommendation was based
on a strong backing by a posthoc data analysis, demonstrating a lack
of efﬁcacy within the selected trials of IA-HA treatment [9].
In contrast, the NICE and NCC-CC guidelines suggested some
potential efﬁcacy of IA-HA treatment; however, the variability in
trial quality made these results unclear. Instead, NICE and NCC-CC
recommended against IA-HA treatment based on cost-effectiveness,
and not efﬁcacy [11,12]. It was generally agreed upon throughout the
guidelines that the safety proﬁle of IA-HA treatment was acceptable;
however, OARSI suggested that a lack of deﬁnitive safety evidence
was a factor in the work group's recommendation decision [10]. The
heterogeneity of the evidence utilized by each guideline resulted in
conﬂicting and inconsistent recommendations regarding the use of
IA-HA treatment.
Further inconsistencies within the guidelines arose from vari-
able methodologies in assessment of clinical signiﬁcance from the
included evidence. No clear “standard” method is available for
assessing trial outcomes, leaving each organization to decide
which assessment methodology they believe to be the most
appropriate. This lack of a standard methodology results in
conﬂicting opinions regarding the appropriateness of potential
assessment methods. Although ﬁve of 10 guidelines used a stand-
ardized mean difference as an assessment of trial outcomes, there
was not a consistent agreement on the most appropriate assess-
ment. The AAOS described assessment of trial outcomes using
minimum clinically important improvement (MCII) and minimum
clinically important difference (MID) derived values from Tubach
et al. [46] and Angst et al. [47] as the most appropriate method of
trial outcome assessment [9,19]; however, the NICE guideline
criteria explicitly states that its work group believed that MID
values such as those from Tubach et al. [46] are not appropriate for
the purposes of meta-analysis and guideline development [11].
Heterogeneity in recommendation formation was also noted, as
the modes in which the working group formulated their clinical
recommendations for each CPG were inconsistent.
In order to limit the potential for personal experience bias and
evidence misinterpretation in CPG formation, it has been sug-
gested that a robust and multidisciplinary working group should
be used in CPG development [6]. The organizations that formed
the included guidelines varied largely in what they believed to be a
robust and multidisciplinary work group. The work groups varied
with from the inclusion of one to seven represented clinical
professions, demonstrating an unclear standard of professions to
be included in the work group for knee OA CPGs. The consideration
of patient values and preferences is a key factor in clinical decision
making [4,7]; however, many guidelines neglected to include a
patient advocate within the CPG formulation process.
Previous reports have highlighted the variability in knee OA
CPG quality [48,49]. These reports have used the AGREE guideline
appraisal tools to demonstrate that current CPGs are variable in
their quality, which is consistent with the ﬁndings of our report.
Previous work has described the differences in the methodologies
utilized in CPG development for knee OA as well. The strengthsand weaknesses of commonly used recommendation formation
methodologies have been outlined [50]; however, consensus
regarding the most appropriate methodology is lacking. The
current report has aimed to address these issues for IA-HA CPG
recommendations. Furthermore, other authors have reported that
incorporation of patients in CPG development and making clear
tools for recommendation implementation are important for
increasing the validity and effectiveness of CPGs in knee OA
[48,50]. It has also been suggested that in the guideline develop-
ment process, working groups should follow the AGREE II checklist
to ensure the resulting CPG will be of acceptable quality [48].
The current appraisal is limited by the low potential for
reproduction of the search strategy used to identify relevant
guidelines. A very general search was used to identify CPGs for
knee OA that speciﬁcally addressed the use of IA-HA treatment.
This search was used because of its efﬁciency in ﬁnding CPGs
directly addressing IA-HA use, as systematic searches of databases
provided numerous CPGs that did not address this treatment
speciﬁcally. We believe that this search was successful, capturing
the appropriate high-impact guidelines within the knee OA ﬁeld.
The current appraisal is strengthened by is its comprehensive
analysis of the methodology used by current knee OA CPGs in
addition to the use of the AGREE II assessment tool. Many of the
previously published guideline appraisals utilize quality assess-
ment tools such as the AGREE II system but do not report on the
variability in trial methodology used throughout the guidelines.
As the AGREE II tool does not address inter-guideline variability in
methodology, this study provides a beneﬁcial analysis of the
heterogeneity in guideline development.Conclusion
The general lack of a standard and consistent methodology in
evidence inclusion, evidence assessment, recommendation forma-
tion, and work group composition for CPG development are seen
to be the causes of inconsistent CPG recommendations, regarding
IA-HA treatment for knee OA. The lack of consensus within the
IA-HA treatment recommendations makes it difﬁcult for clinicians
to identify which guidelines should be followed when deciding to
treat knee OA with IA-HA. Clinicians should use caution when
adhering to CPGs that provide strong recommendations based on
methodologies that are not consistent throughout the available
CPG literature. Strong recommendations formulated using meth-
odologies that have no consensus throughout available CPGs result
in inconsistent opinions regarding the appropriateness of IA-HA
treatment. The variability in opinion regarding IA-HA appropriate-
ness caused by the inconsistent CPG methodologies and recom-
mendations leads to confusion among clinicians, consequently
leading to decreased patient access to available treatments. There
is a need for an agreed upon standard “appropriate methodology”
for OA CPG development in order to prevent the development of
conﬂicting recommendations for IA-HA treatment for knee OA and
assure that clinical professionals and patients utilizing these
guidelines are making the most appropriate decisions as possible.Disclosures
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